Accès ouvert
2025
article
OpenAlex
Frederik Lars Giesel, Stefan Alexander Koerber, Boris Alexander Hadaschik, Selina Kiefer et autres
Abstract Purpose Clinically accurate detection of prostate cancer (PCa) metastases is crucial for management of high-risk PCa patients scheduled for radical prostatectomy. We determine the safety and diagnostic accuracy of pre-operative 68 Ga-PSMA-11 PET/CT imaging in newly diagnosed high-risk PCa and assess …
de, jp, at, ch
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Ute Hennrich, Laurène Wagner, Harun Taş, Luciana Kovacs et autres
Locametz®/Illuccix®/GozellixTM (Novartis AG (Basel, Switzerland) and Telix Pharmaceuticals, Ltd. (Melbourne, Australia), all three [68Ga]Ga-PSMA-11), Pylarify®/Pylclari® (Progenics Pharmaceuticals, Inc. (New York, USA) and Curium PET France SA (Paris, France), both [18F]DCFPyL), Radelumin® (ABX GmbH (Radeberg, Germany), [18F]PSMA-1007), and Posluma® (Blue Earth Diagnostics, Ltd. …
de
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Ute Hennrich, Matthias Eder
In March 2022, [177Lu]Lu-PSMA-617 (PluvictoTM) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other therapy options (such as inhibition …
de
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Ute Hennrich, Matthias Eder
For the positron emission tomography (PET) imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. Almost 10 years after its discovery, [68Ga]Ga-PSMA-11 has been approved in the United States by the Food and Drug …
de
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Ines Katzschmann, Heike Marx, Klaus Kopka, Ute Hennrich
For the PET imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. [18F]PSMA-1007, a radiopharmaceutical labeled with fluorine-18, has excellent properties for the detection of prostate cancer. Essential for the human use of a …
de
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Ute Hennrich, Martina Benešová
In the United States, [68Ga]Ga-DOTA-TOC has been approved by the Food and Drug Administration (FDA) in 2019 as the first 68Ga-radiopharmaceutical for imaging of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors while employing positron emission tomography (PET). In Europe (Austria, Germany, France), …
de
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Ute Hennrich, Klaus Kopka
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors. Using the concept of PRRT, Lutathera® combines the …
de
(code pays fourni par la source)
2019
article
OpenAlex
Claus Zippel, Oliver C. Neels, Ute Hennrich, Frederik Lars Giesel et autres
Zusammenfassung Ziel des Aufsatzes ist es, wesentliche gesetzliche und regulatorische Aspekte zu beleuchten, die bei multizentrischen klinischen Prüfungen mit kurzlebigen PSMA-PET-Radiopharmaka im Hinblick auf die Etablierung einer dezentralen Herstellung des klinischen Prüfpräparats zu beachten sind. Solche prospektiven Studien spielen in der nuklearmedizinischen …
de
(code pays fourni par la source)
2019
conference-paper
OpenAlex
Claus Zippel, OC Neels, Ute Hennrich, Gesine Kabuss et autres
Ziel/Aim: Die Entwicklung innovativer PSMA-PET-Tracer zur nicht-invasiven PCa-Bildgebung und -Behandlung trägt dazu bei, dass zunehmend nuklearmedizinische Multicenter-Studien mit den vielversprechendsten PSMA-Liganden initiiert werden. Bei prospektiven Studien zu kurzlebigen Radiopharmaka wie [ 68 Ga]Ga-PSMA-11 ist vor Patienteneinschluss zunächst eine Struktur zu etablieren, durch …
de
(code pays fourni par la source)
Accès ouvert
2014
article
OpenAlex
Matthias Eder, Oliver C. Neels, Miriam J. Müller, Ulrike Bauder‐Wüst et autres
The detection of prostate cancer lesions by PET imaging of the prostate-specific membrane antigen (PSMA) has gained highest clinical impact during the last years. 68Ga-labelled Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]Ga-PSMA-HBED-CC) represents a successful novel PSMA inhibitor radiotracer which has recently demonstrated its suitability in individual …
de
(code pays fourni par la source)
2012
article
OpenAlex
Ute Hennrich, Lisa Seyler, Martin K.-H. Schäfer, Ulrike Bauder‐Wüst et autres
de
(code pays fourni par la source)
Accès ouvert
2012
article
OpenAlex
Klaus Braun, Marcel Beining, Manfred Wießler, Twan Lammers et autres
With the increase in molecular diagnostics and patient-specific therapeutic approaches, the delivery and targeting of imaging molecules and pharmacologically active agents gain increasing importance. The ideal delivery system does not exist yet. The realization of two features is indispensable: first, a locally …
de, nl, us
(code pays fourni par la source)